<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30184039</article-id><article-id pub-id-type="pmc">6122757</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0253</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>The Effect of Dexmedetomidine on the Acute Pain After Cardiothoracic
Surgeries: A Systematic Review</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Habibi</surname><given-names>Valiollah</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Kiabi</surname><given-names>Farshad Hasanzadeh</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="c1"/><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Sharifi</surname><given-names>Hassan</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>PhD</role></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of Cardiac Surgery, Faculty of Medicine, Mazandaran
University of Medical Sciences, Sari, Iran.</aff><aff id="aff2">
<label>2</label> Department of Anesthesiology, Faculty of Medicine, Mazandaran
University of Medical Sciences, Sari, Iran.</aff><aff id="aff3">
<label>3</label> Department of Medical Surgical Nursing, Faculty of Nursing,
Iranshahr University of Medical Sciences, Iranshahr, Iran.</aff><author-notes><corresp id="c1">Correspondence Address: Farshad Hasanzadeh Kiabi, Department of
Anesthesiology, Faculty of Medicine, Mazandaran University of Medical Sciences,
Sari, Iran. Email: <email>hasanzadehkiabi@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jul-Aug</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jul-Aug</season><year>2018</year></pub-date><volume>33</volume><issue>4</issue><fpage>404</fpage><lpage>417</lpage><history><date date-type="received"><day>24</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>08</day><month>3</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Acute post-operative pain remains a troublesome complication of
cardiothoracic surgeries. Several randomized controlled trials have examined
the efficacy of dexmedetomidine as a single or as an adjuvant agent before,
during and after surgery. However, no evidence-based conclusion has been
reached regarding the advantages of dexmedetomidine over the other
analgesics.</p></sec><sec><title>Objective</title><p>To review the effect of dexmedetomidine on acute post-thoracotomy/sternotomy
pain.</p></sec><sec><title>Methods</title><p>Medline, SCOPUS, Web of Science, and Cochrane databases were used to search
for randomized controlled trials that investigated the analgesia effect of
dexmedetomidine on post-thoracotomy/sternotomy pain in adults' patients. The
outcomes were postoperative pain intensity or incidence, postoperative
analgesia duration, and the number of postoperative analgesic
requirements.</p></sec><sec><title>Results</title><p>From 1789 citations, 12 trials including 804 subjects met the inclusion
criteria. Most studies showed that pain score was significantly lower in the
dexmedetomidine group up to 24 hours after surgery. Two studies reported the
significant lower postoperative analgesia requirements and one study
reported the significant lower incidence of acute pain after surgery in
dexmedetomidine group. Ten studies found that the total consumption of
narcotics was significantly lower in the dexmedetomidine group. The most
reported complications of dexmedetomidine were nausea/vomiting, bradycardia
and hypotension.</p></sec><sec><title>Conclusion</title><p>Dexmedetomidine can be used as a safe and efficient analgesic agent for
reducing the postoperative pain and analgesic requirements up to 24 hours
after cardiothoracic surgeries. However, further well-designed trials are
needed to find the optimal dosage, route, time, and duration of
dexmedetomidine administration.</p></sec></abstract><kwd-group><kwd>Pain, Postoperative</kwd><kwd>Thoracic Surgery</kwd><kwd>Cardiovascular Surgical Procedures</kwd><kwd>Thoracotomy</kwd><kwd>Sternotomy</kwd><kwd>Adrenergic Alpha-2 Receptor Agonists</kwd><kwd>Dexmedetomidine</kwd><kwd>Analgesia</kwd></kwd-group></article-meta></front><body><table-wrap id="t8" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
graft</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CTS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiothoracic
surgeries</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">DEX</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Dexmedetomidine</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">FDA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Food and Drug
Administration</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ICU</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intensive care unit</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NRS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Numerical rating
scales</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PCIA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Patient controlled
intravenous analgesia</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">POP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Postoperative pain</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RCTs</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Randomized controlled
trials</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SUF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Sufentanil</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">VAS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Visual analogue
scale</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">VRS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Verbal rating
scales</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Acute pain is one of the intense complications after cardiothoracic surgeries (CTS),
which can delay patients' recovery and may increase patients' morbidity and
mortality<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.
Acute pain after CTS has been determined as a main risk factor in the pathogenesis
of numerous postoperative side effects such as respiratory failure<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref>]</sup>. Inadequately controlling the postoperative pain (POP)
increase the risk of pulmonary complications due to the diaphragmatic dysfunction
and incapability of patients to take large-volume breaths<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. Consequently, effective
pain management can play a vital role in reducing patients discomfort and,
therefore, it should be a prerequisite for promoting respiratory and cardiac
function of patients undergoing CTS<sup>[<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>]</sup>.</p><p>In last decades, several pharmacological and nonpharmacological interventions have
been developed to reduce acute POP including opioids, paravertebral and epidural
infusion of local anesthetics, sedatives, nerve blockades, intrapleural analgesia,
nerve stimulation, ketamine, gabapentinoids, selective COX-2 inhibitors,
nonsteroidal anti-inflammatory drugs, alpha2- agonists, and
aromatherapy<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r7" ref-type="bibr">7</xref>]</sup>. However, the effectiveness
and efficacy of those interventions are variable among studies. Many of those
interventions, particularly opioids, have several side effects that can impair
cardiac and respiratory function following surgery<sup>[<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref>]</sup>. In
addition, the benefits of thoracic epidural analgesia as a gold standard for
controlling POP have been questioned because of higher risk of severe cardiovascular
complications<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. Hence, acute pain management continues to be a
challenge in CTS.</p><p>Recently, some opioid-sparing analgesics such as dexmedetomidine (DEX) have
demonstrated a promising opportunity to decrease the postoperative complications
particularly impairment of respiratory function<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>]</sup>.
DEX has been recommended for sedating agitated patients in the intensive care unit
(ICU)<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>,
because it does not depress the respiratory and cognitive
dysfunctions<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r12" ref-type="bibr">12</xref>]</sup>.</p><p>Several randomized controlled trials (RCTs) have examined the efficacy of DEX on POP
after CTS. However, a clear advantage of DEX over other analgesics has not been
evident so far. Therefore, the aim of this study was to review the effectiveness of
DEX for reducing the acute post-thoracotomy/sternotomy pain in comparison with other
analgesics.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This systematic review was accomplished in accordance to the PRISMA: the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
guidelines<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. Our PICOS research question was formulated as follows:
(P) patients undergoing thoracotomy or sternotomy; (I) dexmedetomidine; (C) placebo
or other analgesic drug; (O) postoperative pain; (S) trial.</p><sec><title>Eligibility Criteria</title><p>Inclusion criteria were: (1) Study designed with RCT; (2) Patients undergoing
thoracotomies or sternotomy; (3) Study with at least two groups that compared
perioperative (preoperative, intraoperative, or postoperative) administration of
DEX with other analgesic agents or placebo; (4) DEX with different routes,
dosage, frequency, and duration of administration; (5) POP should be one of the
study outcomes.</p><p>Conference proceedings, abstracts, letters, and commentaries were excluded. In
addition, quasi-randomized trials, nonrandomized trials, studies not published
in English and animal trials were excluded.</p></sec><sec><title>Outcomes Measurement</title><p>Primary outcomes were (1) POP intensity measured by visual analogue scale (VAS)
or verbal or numerical rating scales (VRS or NRS) or POP incidence; (2) number
of postoperative narcotic and/or analgesic requirements; (3) postoperative
analgesia duration. Secondary outcomes were: (1) number of DEX-associated major
adverse events.</p></sec><sec><title>Information Sources</title><p>A predefined Medline-based strategy was developed to search the following
databases (<xref ref-type="app" rid="app1">Appendix 1</xref>): Medline via
PubMed, SCOPUS, Institute for Scientific Information (ISI) Web of Science,
Cochrane Central Register of Controlled Trials, and Cochrane Database of
Systematic Reviews. Reference sections of the included trials, published
meta-analyses, and pertinent review articles were hand searched to find
additional articles.</p></sec><sec><title>Search Strategy</title><p>Both subject headings and free-text terms were used in searching the databases.
The search strategy contained two components: (1) dexmedetomidine OR adrenergic
alpha-2 receptor agonists; (2) pain OR analgesia. These two components were
combined using the Boolean operator, "AND", to obtain any link between them. We
searched the databases without publication date restriction from the inception
of each database until June 12, 2017.</p></sec><sec><title>Study Selection and Data Collection Process</title><p>Two authors (FHK-HS) searched the databases using search strategy (n=1789). They
independently screened the titles and abstracts of retrieved studies against the
predetermined inclusion criteria for selecting relevant articles (1221 title
rejected straightaway because of duplicate or irrelevant study. Reasons for
excluding an article were documented. The full-text of potentially relevant
articles, which met the inclusion criteria, was reviewed for comprehensive
assessment against the inclusion criteria. Disagreement about study selection
was resolved by discussion and consensus with the third author (VH). In cases
that additional data was required, the corresponding author of the study was
contacted. Each included study was independently evaluated by three authors
(VH-FHK-HS) for content. Then, data extraction table was completed by relevant
data of studies that met the inclusion criteria. None of the review authors
(VH-FHK-HS) was blinded to reference details during the study selection
process.</p></sec><sec><title>Assessing Risk of Bias</title><p>The methodological quality of the selected studies was independently evaluated by
two authors (VH-FHK) using the Cochrane Collaboration's tool for assessing risk
of bias (<xref rid="t1" ref-type="table">Table 1</xref>). As recommended by tool
developer<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup>, we did not determine the total quality score for
each domain, however, in interpreting the results, the limitations of each study
were considered.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Cochrane Collaboration's tool for assessing risk of bias.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1">Study</th><th align="center" rowspan="2" colspan="1">Random sequence generation</th><th align="center" rowspan="2" colspan="1">Allocation concealment</th><th align="center" colspan="2" rowspan="1">Blinding of</th><th align="center" rowspan="2" colspan="1">Incomplete outcome data
(attrition)</th><th align="center" rowspan="2" colspan="1">Selective reporting</th><th align="center" rowspan="2" colspan="1">Other bias</th></tr><tr><th align="center" rowspan="1" colspan="1">Participants and personnel</th><th align="center" rowspan="1" colspan="1">Outcome assessment</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Dong et al.<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>, 2017</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Unclear</td></tr><tr><td align="left" rowspan="1" colspan="1">Dutta et al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>, 2017</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Unclear</td></tr><tr><td align="left" rowspan="1" colspan="1">Jabbary Moghaddam et al.<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>,
2016</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">High</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">High</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Unclear</td></tr><tr><td align="left" rowspan="1" colspan="1">Cai et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>, 2016</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">High</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td></tr><tr><td align="left" rowspan="1" colspan="1">Priye et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>, 2015</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Unclear</td></tr><tr><td align="left" rowspan="1" colspan="1">Ren et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>, 2015</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1">Ramsay et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>, 2014</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Unclear</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdel-Meguid<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>, 2013</td><td align="center" rowspan="1" colspan="1">High</td><td align="center" rowspan="1" colspan="1">High</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td></tr><tr><td align="left" rowspan="1" colspan="1">Elhakim et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>, 2010</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td></tr><tr><td align="left" rowspan="1" colspan="1">Ghandi et al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>, 2005</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td></tr><tr><td align="left" rowspan="1" colspan="1">Wahlander et al.<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>, 2005</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1">Venn et al.<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>, 1999</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Unclear</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Study Selection</title><p>From 1789 citations identified through database searches, 124 articles were
examined in more detail. Twelve studies met the inclusion
criteria<sup>[<xref rid="r14" ref-type="bibr">14</xref>-<xref rid="r25" ref-type="bibr">25</xref>]</sup>. The total number of
subjects was 804 (DEX, n=419; Control, n=385). Sample sizes ranged from 14 to 54
subjects for each group. The number of patients undergoing general surgery from
the total sample size in one study was excluded<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>. The flow chart to
select the final 12 trials is detailed in <xref ref-type="fig" rid="f1">Figure
1</xref>.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>PRISMA flow diagram of search strategy and study selection.</p></caption><graphic xlink:href="rbccv-33-04-0404-g01"/></fig>
</p><p>Study Characteristics</p><p>All twelve trials were RCT with two parallel groups, except for one study that
consist of two groups with different dosages of DEX and a third control
group<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>. Among the 12 RCTs, the VAS was the most frequently
used scale to determine the intensity of POP. Eight studies used the
VAS<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r20" ref-type="bibr">20</xref>,<xref rid="r21" ref-type="bibr">21</xref>,<xref rid="r23" ref-type="bibr">23</xref>-<xref rid="r25" ref-type="bibr">25</xref>]</sup>,
three used the NRS<sup>[<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r19" ref-type="bibr">19</xref>]</sup> and one of them used the VRS<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>.</p><p>Patients' mean age among all trials was 55.89 years (range between 34.4 and 67.7
years). Trials included a total number of 566 (70.4%) male and 228 (28.4%)
female, for the last 110 subjects. An error in reported data in one study was
found<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup> (<xref rid="t1" ref-type="table">Table 1</xref>)
and one study did not report the male/female ratio. Generally, the number of
male patients was greater than female.</p><p>No statistically significant difference was found between the DEX and control
groups regarding the baseline characteristics of patients in all included
studies. <xref rid="t2" ref-type="table">Table 2</xref> depicts the details for
perioperative data and anesthesia techniques.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Preoperative data, monitoring and anesthesia.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="center" colspan="5" rowspan="1">Anesthesia</th></tr><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Premedication</th><th align="center" rowspan="1" colspan="1">Induction</th><th align="center" rowspan="1" colspan="1">Maintenance</th><th align="center" rowspan="1" colspan="1">Neuromuscular<break/>relaxation</th><th align="center" rowspan="1" colspan="1">Rescue analgesic use</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Dong et al.<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>, 2017</td><td align="center" rowspan="1" colspan="1">MID 0.05 mg/kg/IV 2h preop</td><td align="center" rowspan="1" colspan="1">0.4 mcg/kg SUF, PROP, SEVO</td><td align="center" rowspan="1" colspan="1">SUF 1 mcg/kg/h and PROP, SEVO, oxygen, and
CIS</td><td align="center" rowspan="1" colspan="1">CIS</td><td align="center" rowspan="1" colspan="1">IV injection of meperidine 50 mg</td></tr><tr><td align="left" rowspan="1" colspan="1">Dutta et al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>, 2017</td><td align="center" rowspan="1" colspan="1">Alprazolam on the night before and the morning of
surgery</td><td align="center" rowspan="1" colspan="1">FEN and PROP</td><td align="center" rowspan="1" colspan="1">ISO and air/oxygen mixture</td><td align="center" rowspan="1" colspan="1">VECO</td><td align="center" rowspan="1" colspan="1">MO 3 mg IV</td></tr><tr><td align="left" rowspan="1" colspan="1">Jabbary Moghaddam et al.<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>,
2016</td><td align="center" rowspan="1" colspan="1">___</td><td align="center" rowspan="1" colspan="1">FEN 2 &#x000b5;g/kg, MID 0.05 mg/kg, LIDO, and ETO
1 - 2 mg/kg</td><td align="center" rowspan="1" colspan="1">Oxygen and ISO with 1% - 1.2% end-tidal
concentration and FEN</td><td align="center" rowspan="1" colspan="1">CIS 1 - 2<break/>&#x000b5;g/kg/min</td><td align="center" rowspan="1" colspan="1">DEX: 0.5 &#x000b5;g/kg/hour<break/>Con: MID 0.05
mg/kg</td></tr><tr><td align="left" rowspan="1" colspan="1">Cai et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>, 2016</td><td align="center" rowspan="1" colspan="1">___</td><td align="center" rowspan="1" colspan="1">PROP 2 mg/kg, SUF 0.3 mcg/kg</td><td align="center" rowspan="1" colspan="1">SEVO with a minimal alveolar concentration of 1.0
to 1.3</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">CIS 0.2 mg/kg</td><td align="center" rowspan="1" colspan="1">Ketorolac 30 mg or tramadol (100 mg)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Priye et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>, 2015</td><td align="center" rowspan="1" colspan="1">Oral gabapentin 600 mg 45 min before surgery</td><td align="center" rowspan="1" colspan="1">MID 0.1 mg/kg, FEN 10 meg/kg, PROP 100
mcg/kg/min</td><td align="center" rowspan="1" colspan="1">___</td><td align="center" rowspan="1" colspan="1">VECO 0.2<break/>mg/kg</td><td align="center" rowspan="1" colspan="1">FEN 25 mcg intermittent bolus</td></tr><tr><td align="left" rowspan="1" colspan="1">Ren et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>, 2015</td><td align="center" rowspan="1" colspan="1">MID 0.5-2 mg</td><td align="center" rowspan="1" colspan="1">PROP 1.5-2 mg/kg, SUF (TCI 0.2 ng/mL),<break/>and
CIS 0.2 mg/kg</td><td align="center" rowspan="1" colspan="1">PROP (TCI 2.4-3.0 mcg/mL), DEX 0.4-0.6 mcg/kg/h)
and SUF (TCI 0.2-0.24 ng/mL)</td><td align="center" rowspan="1" colspan="1">CIS 0.04<break/>mg/kg every hour</td><td align="center" rowspan="1" colspan="1">30 mg intravenous ketorolac and tramadol (100
mg)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ramsay et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>, 2014</td><td align="center" rowspan="1" colspan="1">___</td><td align="center" rowspan="1" colspan="1">PROP, FEN, and SEVO</td><td align="center" rowspan="1" colspan="1">___</td><td align="center" rowspan="1" colspan="1">VECO</td><td align="center" rowspan="1" colspan="1">___</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdel-Meguid<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>, 2013</td><td align="center" rowspan="1" colspan="1">LOR 2 mg orally one night before surgery and MO
0.1 mg/kg IM 2h Preop</td><td align="center" rowspan="1" colspan="1">SUF 1-1.5 &#x000b5;g/kg, MID 0.05-0.1 mg/kg</td><td align="center" rowspan="1" colspan="1">SEVO plus SUF 0.2 mcg/kg/hour, MID 1.5
mcg/kg/hour, and ROCU 0.5 mg/kg/hour</td><td align="center" rowspan="1" colspan="1">ROCU 0.9<break/>mg/kg</td><td align="center" rowspan="1" colspan="1">___</td></tr><tr><td align="left" rowspan="1" colspan="1">Elhakim et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>, 2010</td><td align="center" rowspan="1" colspan="1">MID 0.07 mg/kg IM half an hour before
surgery</td><td align="center" rowspan="1" colspan="1">FEN 3 mg/kg, thiopental 3-5<break/>mg/kg and</td><td align="center" rowspan="1" colspan="1">End-tidal concentration of 0.3-0.5 vol% ISO</td><td align="center" rowspan="1" colspan="1">Pancuronium 0.1 mg/kg</td><td align="center" rowspan="1" colspan="1">Paracetamol</td></tr><tr><td align="left" rowspan="1" colspan="1">Ghandi et al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>, 2005</td><td align="center" rowspan="1" colspan="1">MO 0.1 mg/kg/IM with oral LOR 1 mg</td><td align="center" rowspan="1" colspan="1">REM 1 &#x000b5;/kg, MID 0.1 mg/kg and CIS 0.15
mg/kg</td><td align="center" rowspan="1" colspan="1">REM 0.1 - 0.05 &#x000b5;/kg/minute, propofol 50 -
75 &#x000b5;g/kg/minute, MID 0.02 - 0.05 &#x000b5;/kg/minute, CIS
and low dose of SEVO</td><td align="center" rowspan="1" colspan="1">Not reported by authors</td><td align="center" rowspan="1" colspan="1">Not reported by authors</td></tr><tr><td align="left" rowspan="1" colspan="1">Wahlander et al.<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>, 2005</td><td align="center" rowspan="1" colspan="1">___</td><td align="center" rowspan="1" colspan="1">PROP 2 to 3 mg/kg, FEN 2 mcg/kg</td><td align="center" rowspan="1" colspan="1">Oxygen, nitrous oxide, ISO, FEN, and VECO</td><td align="center" rowspan="1" colspan="1">VECO 0.1<break/>mg/kg</td><td align="center" rowspan="1" colspan="1">3 mL 0.125% (3.75 mg) bupivacaine</td></tr><tr><td align="left" rowspan="1" colspan="1">Venn et al.<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>, 1999</td><td align="center" rowspan="1" colspan="1">___</td><td align="center" rowspan="1" colspan="1">Remifentanil</td><td align="center" rowspan="1" colspan="1">MO</td><td align="center" rowspan="1" colspan="1">___</td><td align="center" rowspan="1" colspan="1">MID 0.01-0.2 mg/kg/h and MO 2 mg</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>ABG=atrial blood gas; BIS=bispecteral index; BP=blood pressure;
CIS=cisatracurium; DEX=dexmedetomidine; ECG=electrocardiogram;
ETO=etomidate; FEN=fentanyl; h=hour; HR=heart rate; ISO=isoflurane;
IM=intramuscular; IV=intravenous; LIDO=lidocaine; LOR=lorazepam;
MID=midazolam; MO=morphine; NIABP=noninvasive blood pressure;
PROP=propofol; REM=remifentanil; ROCU=rocuronium; SEVO=sevoflurane;
SpO2=pulse oxygen saturation; SUF=sufentanil; VECO=vecuronium</p></fn></table-wrap-foot></table-wrap><p>Types of surgery were thoracic surgery (n=425)<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r19" ref-type="bibr">19</xref>,<xref rid="r20" ref-type="bibr">20</xref>,<xref rid="r22" ref-type="bibr">22</xref>,<xref rid="r24" ref-type="bibr">24</xref>]</sup> and cardiac surgery (n=379)<sup>[<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r21" ref-type="bibr">21</xref>,<xref rid="r23" ref-type="bibr">23</xref>,<xref rid="r25" ref-type="bibr">25</xref>]</sup>. As depicted in <xref rid="t3" ref-type="table">Table 3</xref>, only eight studies including 466 subjects reported their
surgeries as elective. Subcategories of thoracotomy operations were esophageal
neoplasia resection (n=200), lobectomy (n=77), pneumonectomy (n=26), mediastinal
mass or cancer (n=24), pneumothorax (n=7), cyst excision (n=5), decortication
(n=4), and bullectomy (n=1), pleurectomy (n=14), other non-categorized major
open thoracotomy surgeries (n=67). Subcategories of cardiac surgery were on-pump
coronary artery bypass bypass graft (CABG), off-pump CABG, valve surgery, and
atrial septal defect closure. We could not determine the exact number of
patients in each subcategory of cardiac surgery because some studies did not
report the number of patients in each category.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Characteristics of included trials.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="center" rowspan="1" colspan="1">Design</th><th align="center" rowspan="1" colspan="1">Fixed TRT (drug) for all groups</th><th align="center" rowspan="1" colspan="1">Postoperative pain outcome assessment and time
points</th><th align="center" rowspan="1" colspan="1">Authors conclusion / DEX reported
complications</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Dong et al.<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>, 2017</td><td align="left" rowspan="1" colspan="1">Two parallel groups, N= 60<break/>G1: PCIA
(n=30)<break/>G2: DEX 4 mcg/kg added to PCIA
(n=30)<break/>Surgery (n of CO, n of DEX): elective major open
thoracotomy operations include esophageal neoplasia resection
(16, 17), lobectomy (6, 7), pneumonectomy (1, 2), mediastinal
mass (2, 2), and pneumothorax (5, 2)<break/>INT duration: the
first 48h postop period<break/>Mean of age: G1=57.3 G2= 55.4,
range=32-65 y<break/>M/F: 19/31</td><td align="left" rowspan="1" colspan="1">PCIA program:<break/> Drug: SUF 3.0 mcg/kg plus 8mg
ondansetron<break/>Loading: 20 ml<break/>On demand: 2
ml<break/>Lock-out: 10 min<break/>Background: 4 ml</td><td align="left" rowspan="1" colspan="1">Outcomes: SUF consumption in the 48h postop period,
the mean of pain intensity, the number of PCIA self-administer
and meperidine injection<break/> Interval: 2, 6, 12, 24, 36 and
48h postop period<break/>Scales: VAS</td><td align="left" rowspan="1" colspan="1">The combination of DEX and SUF in PCIA reduces SUF
consumption, the pain intensity, and supplemental analgesic
requirements, while maintaining a good hemodynamic
stability.<break/> DEX reported complications: bradycardia,
hypotension, over sedation</td></tr><tr><td align="left" rowspan="1" colspan="1">Dutta et al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>, 2017</td><td align="left" rowspan="1" colspan="1">Two parallel groups, N= 30<break/>G1: Standard drug
(n=15)<break/>G2: a bolus of DEX 1 mcg/kg over 3 to 5 minutes
followed by an infusion of 0.2 mcg/kg/hour added to standard
drug (n=15)<break/>Surgery (n of CO, n of DEX): elective lung
surgeries via anterolateral or posterolateral thoracotomy
including lobectomy (2, 8), pneumonectomy (5, 5), cyst excision
(5, 0), decortication (2, 2), and bullectomy (1, 0)<break/>INT
duration: the first 24h postop period<break/>Mean of age:
G1=34.4 G2= 42.1, range=18-70<break/>M/F: 20/10</td><td align="left" rowspan="1" colspan="1">Standard drug:<break/> A bolus of 15 mL of 0.75%
ROPI over 3 to 5 minutes, followed by an infusion of 0.2% ROPI
at 0.1 mL/kg/h<break/>Thoracic paravertebral block by lignocaine
2% (3 mL) with adrenalin up to 72 hours after surgery</td><td align="left" rowspan="1" colspan="1">Outcomes: Intraoperative anesthetic drug
requirement, pain scores,&#x000a0; rescue analgesic use requirement, and
incidence of pain syndrome in 2 months<break/> Intervals:1, 2,
3, 4, 8, 12, 16, 20, and 24h postop period<break/>Scales:
VAS</td><td align="left" rowspan="1" colspan="1">Paravertebral DEX administration is associated with
lower number of rescue analgesia, morphine required, total
intraoperative fentanyl dose, propofol induction dose, and lower
postop pain in 1, 2, 4, and 8 hours.<break/> DEX fails to lower
the incidence of post-thoracotomy pain syndrome.<break/>DEX
reported complications: bradycardia, hypotension, over
sedation</td></tr><tr><td align="left" rowspan="1" colspan="1">Jabbary Moghaddam et al.<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>,
2016</td><td align="left" rowspan="1" colspan="1">Two parallel groups; N=104<break/>G1: IV infusion
of DEX 0.5 mcg/kg/h (n=50)<break/>G2: NS (n=54)<break/>Surgery
(n of CO, n of DEX): elective CABG<break/>INT duration: from the
initiation of anesthesia until extubation in the ICU<break/>Mean
of age: G1=57.3, G2= 55.4<break/>M/F: 71/33</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">Outcomes: the NRS score after surgery and the
incidence of postop pain by telephone interview<break/>
Intervals: two months<break/>scale: NRS and BPI</td><td align="left" rowspan="1" colspan="1">The incidence of postop was significantly lower in
the DEX group than that of the control group.<break/>
Pre-emptive intraoperative DEX may reduce pain<break/>DEX
reported complications: not reported</td></tr><tr><td align="left" rowspan="1" colspan="1">Cai et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>, 2016</td><td align="left" rowspan="1" colspan="1">Two parallel groups; N= 94<break/>G1: DEX at a
loading dose of 1 mcg/kg for 10 minutes, followed by continuous
infusion at 0.5 mcg /kg/h (n=46)<break/>G2: NS
(n=48)<break/>Surgery (n of CO, n of DEX): thoracic surgeries
including thoracoscopic lobectomy (12, 10), open thoracic
lobectomy (4, 6), incision of esophageal cancer (32,
30)<break/>INT duration: the first 48h postop period<break/>Mean
of age: G1=54.6 G2= 55.4, range=18-65<break/>M/F: 94/0</td><td align="left" rowspan="1" colspan="1">PCIA program:<break/> Drug: SUF 0.8
mg/mL<break/>Loading: 2 mL<break/>On demand:
none<break/>Lock-out: 5 min<break/>Background: a 4-hour
limit<break/>of 30 to 40 mL of SUF</td><td align="left" rowspan="1" colspan="1">Outcomes: The mean of pain at rest and with
coughing and dosage of SUF during surgery<break/> Intervals: at
arrival, 1, 4h, and every 4h thereafter until the 48h postop
period<break/>Scales: NRS</td><td align="left" rowspan="1" colspan="1">Intraoperative DEX can reduce the opioid
requirement and pain intensity, as well as reduce the cumulative
dosage of SUF, NRS at rest, and NRS with coughing
scores.<break/> DEX reported complications: bradycardia</td></tr><tr><td align="left" rowspan="1" colspan="1">Priye et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>, 2015</td><td align="left" rowspan="1" colspan="1">Two parallel groups; N= 64<break/>G1: IV infusion
of DEX 0.4 mcg/kg/h for 12h without a loading dose,
(n=32)<break/>G2: NS (n=32)<break/>Surgery: elective cardiac
surgery using cardiopulmonary bypass (CPB) including coronary
artery bypass graft, valve surgery, and atrial septal defect
closure. (Note: the number of subjects in each category was not
identified by authors)<break/>INT duration: Intraoperative until
the first 24h postop period<break/>Mean of age: G1=41.4 G2=
45.1, range= over 18<break/>M/F: 33/31</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">Outcomes: Postop pain and total fentanyl
consumption Intervals: 6, 12, 18, and 24h Scales: VAS</td><td align="left" rowspan="1" colspan="1">DEX is associated with lower pain score at 0, 6,
12, 18 and 24h postop period and fewer fentanyl consumption than
normal saline. Also, DEX could reduce the incidence of
delirium.<break/> DEX reported complications: without
significant complications</td></tr><tr><td align="left" rowspan="1" colspan="1">Ren et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>, 2015</td><td align="left" rowspan="1" colspan="1">Three parallel groups; N= 125<break/>G1: SUF 0.02
mcg/kg/h, (n=41)<break/>G2: SUF 0.02 mcg/kg/h plus DEX 0.02
mcg/kg/h each (n=41)<break/>G3: SUF 0.02 mcg/kg/h plus IV
infusion of DEX 0.04 mcg/kg/h (n=43)<break/>Surgery (n of CO, n
of DEX1, 2): thoracic surgeries including thoracotomy in
esophageal (one incision) (35, 34, 36) and thoracotomy in
cardiac cancer (6, 7, 7)<break/>INT duration: the first 72h
postop period<break/>Mean of age: G1=59.8, G2= 59.9, G3=60.5,
range=35-65<break/>M/F: 125/0</td><td align="left" rowspan="1" colspan="1">PCIA program:<break/> Drug: SUF 0.8
mg/mL<break/>Loading: 2 mL<break/>On demand:
none<break/>Lock-out: 5 min<break/>Background: 2 ml/h, 4h limit
of 40 ml<break/>Intraoperative DEX: a small bolus of 0.5 mcg/kg
then reduced to 0.5 mg/kg/h</td><td align="left" rowspan="1" colspan="1">Outcomes: cumulative amount of self-administered
SUF and the postop pain intensity scores both at rest and with
coughing<break/> Intervals: 1, 4, 8, 16, 24, 48, and
72h<break/>Scales: NRS</td><td align="left" rowspan="1" colspan="1">Addition of DEX 0.04 mcg/kg/h to SUF improves the
analgesic effect of SUF and is associated with greater patient
satisfaction without side effects. This combination could
decrease the total dosage of SUF during the first 72h after
surgery.<break/> DEX reported complications: without significant
complications</td></tr><tr><td align="left" rowspan="1" colspan="1">Ramsay et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>, 2014</td><td align="left" rowspan="1" colspan="1">Two parallel groups; N= 38<break/>G1: IV infusion
of DEX 0.1 to 0.5 mcg/kg/h, (n=19)<break/>G2: NS
(n=19)<break/>Surgery: major open lateral thoracotomy (Note:
sub-categories of thoracotomy has not been identified by
authors)<break/>INT duration: 18 to 24h postop period<break/>Up
to 24h after that (42-48h postop)<break/>Mean of age: G1=61, G2=
56, range=18-85<break/>M/F: 15/23</td><td align="left" rowspan="1" colspan="1">PCIA<break/> Drug: MO<break/>Protocol: not
reported, but the two groups were similar in the types of PCA
pumps and supplemental opioids
used<break/>Intraoperative:<break/>DEX at 0.2 to 0.5 mcg/kg/h
without bolus until 30 minutes prior to transfer to the
telemetry unit</td><td align="left" rowspan="1" colspan="1">Outcomes: the amount of self-administered opioid
medication and average pain scores<break/> Intervals: 24h after
ICU discharge and 24 to 48h postop<break/>Scales: VAS</td><td align="left" rowspan="1" colspan="1">In comparison with normal saline, DEX is associated
with lower morphine consumption, however, the mean pain scores
between DEX and normal saline groups were similar.<break/> DEX
reported complications: hypotension, bradycardia</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdel-Meguid<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>, 2013</td><td align="left" rowspan="1" colspan="1">Two parallel groups; N= 30<break/>G1:&#x000a0; DEX at 0.5
mcg/kg/h after the induction of anesthesia, that reduced to 0.3
mcg/kg/h on admission in the ICU and continued for 12h post
extubation (n=15)<break/>G2: NS (n=15)<break/>Surgery: elective
coronary artery surgery using OPCAB technique<break/>INT
duration: The first 12h post extubation<break/>Mean of age:
G1=55, G2= 52<break/>M/F: 23/7</td><td align="left" rowspan="1" colspan="1">MO for postop pain management</td><td align="left" rowspan="1" colspan="1">Outcomes: The median of postop pain and total dose
of MO<break/> Intervals: 2, 4, 6, 8, 10, 12h
postop<break/>Scales: VAS</td><td align="left" rowspan="1" colspan="1">DEX showed a better pain control, a lower
consumption of narcotics and earlier extubation time.<break/>
DEX reported complications: not reported</td></tr><tr><td align="left" rowspan="1" colspan="1">Elhakim et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>, 2010</td><td align="left" rowspan="1" colspan="1">Two parallel groups; N= 50<break/>G1: DEX 1 mcg/kg
plus bupivacaine 0.5% via epidural catheter (n=25)<break/>G2:
bupivacaine 0.5% via epidural catheter (n=25)<break/>Surgery (n
of CO, n of DEX): elective open thoracotomy for lung surgery
with one-lung ventilation including right lobectomy (12, 11),
right pleurectomy (7, 7), and right pneumectomy (6,
7)<break/>INT duration: after induction of general anesthesia
until the first 24h postop period<break/>Mean of age: G1=52,
G2=50, range=43-54<break/>M/F: 50/0</td><td align="left" rowspan="1" colspan="1">Drug:<break/> IV crystalloids colloids and fentanyl
bolus dose were added to the epidural medication</td><td align="left" rowspan="1" colspan="1">Outcomes: Postop pain scores, and postop analgesic
use requirement Intervals: at 6, 12, 18, and 24h after
surgery<break/> Scales: VRS</td><td align="left" rowspan="1" colspan="1">Epidural use of DEX decreases the anesthetic
requirements and improves postoperative analgesia as well as
shorter the ICU stay<break/> DEX reported complications: without
significant complications</td></tr><tr><td align="left" rowspan="1" colspan="1">Ghandi et al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>, 2005</td><td align="left" rowspan="1" colspan="1">Two parallel groups; N=100<break/>G1: MO 0.2 mg via
PCIA at 4 ml/h (n=50)<break/>G2: DEX 0.2 mcg/kg via PCIA
(n=50)<break/>Surgery: candidates for open cardiac
surgery<break/>INT duration: after surgery until the first 24h
postop<break/>Mean of age: G1=66.7, G2= 65.4,
range=54-81<break/>M/F: not reported</td><td align="left" rowspan="1" colspan="1">PCIA, but the protocol not reported by authors</td><td align="left" rowspan="1" colspan="1">Outcomes: The mean of postop pain intensity and
intravenous MO consumption<break/> Intervals: 2, 4, 6, 8,10,12,
14, 16 and 18h postop<break/>Scale: VAS</td><td align="left" rowspan="1" colspan="1">DEX is associated with lower pain score in the 2,
4, 6, 8, 10 and 12h postop periods. Male patients experienced
lower pain than female in the DEX group. DEX reduced the IV MO
consumption during ICU stay. DEX shortened the intubation
time.<break/> DEX reported complications: without significant
complications</td></tr><tr><td align="left" rowspan="1" colspan="1">Wahlander et al.<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>, 2005</td><td align="left" rowspan="1" colspan="1">Two parallel groups; N= 28<break/>G1: IV loading
dose of DEX 0.5 mcg/kg over 20 minutes, followed by continuous
IV infusion at 0.4 mcg/kg/h, (n=14)<break/>G2: NS
(n=14)<break/>Surgery: elective thoracotomy for wedge resection,
lobectomy, or pneumonectomy (Note: the number of subjects in
each category was not identified by authors)<break/>INT
duration: the first 24h post ICU<break/>Mean of age: G1=67.7,
G2= 65.7, range= over 18<break/>M/F: 12/16</td><td align="left" rowspan="1" colspan="1">In the operating room, a TEC loaded using 3 mL of
1.5% lidocaine-epinephrine mixture.<break/> PCEA
program:<break/>Loading: 3 mL 0.125% (3.75 mg)
bupivacaine,<break/>Lock-out: 20 min<break/>Background: 4-hour
limit of 30 mL 0.125% (37.5 mg) bupivacaine</td><td align="left" rowspan="1" colspan="1">Outcomes: need for additional epidural bupivacaine
administered by PCEA and the requirement for supplemental
opioids (fentanyl)<break/> Intervals: at admission to SICU or
PACU (zero time point) and then in&#x000a0; 1, 2, 3, 4, 12, 16, and 24h
postop periods<break/>Scales: VAS</td><td align="left" rowspan="1" colspan="1">IV DEX has beneficial analgesic effects on
post-thoracotomy pain when using as an addition to a thoracic
epidural infusion of 0.125% bupivacaine.<break/> It is unable to
decrease the PCEA requirement, but is able to decrease the
requirement for opioids and likelihood of respiratory
depression<break/>DEX reported complications: hypotension and
bradycardia</td></tr><tr><td align="left" rowspan="1" colspan="1">Venn et al.<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>, 1999</td><td align="left" rowspan="1" colspan="1">Two parallel groups; N= 98, cardiac
(n=81)<break/>G1: IV DEX at a loading dose of 1 mcg/kg over 10
min followed by a maintenance infusion rate of 0.2-0.7 mcg/kg/h,
maximum infusion rate of<break/>0.7 mcg/kg/h (n=39)<break/>G2:
NS (n=42)<break/>Surgery: cardiac surgery using cardiopulmonary
bypass (n=81) and general surgery (n=17)<break/>INT duration:
within 1h of arrival on the ICU until the first 24h after
that<break/>Mean of age: G1=63.3, G2= 64.2, range= over
18<break/>M/F: 54/27</td><td align="left" rowspan="1" colspan="1">MID 0.01-0.2 mg/kg/h and MO</td><td align="left" rowspan="1" colspan="1">Outcomes: postoperative analgesia (MO)<break/>
Intervals: hourly up to first 24h postop period<break/>Scales:
VAS</td><td align="left" rowspan="1" colspan="1">Intubated patients receiving DEX required 80% less
MID and 50% less MO<break/> DEX could reduce the requirements
for rescue sedation and analgesia in postop patients for up to
24h.<break/>MO requirement was reduced by half in the DEX
group.<break/>DEX reported complications: bradycardia and
hypotension</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>ABG=arterial blood gas; BP=blood pressure; BPI=brief pain inventory;
C=control; CABG=coronary artery bypass graft; DEX=dexmedetomidine;
G= group; HR=heart rate; ICU=intensive care unit; INT=Intervention;
M/F=male/female number; MO=morphine; NR=not recorded; NRS=numeric
rating scale; NS=normal saline; NV=nausea and vomiting;
OAA=Observer's Assessment of Alertness/Sedation; OPCAB=off&#x02011;pump
coronary artery bypass; PCEA=patient-controlled epidural analgesia;
PCIA=patient-controlled intravenous analgesia; PNRS: pain number
rating scale; Postop=postoperative; Preop=preoperative;
RCT=randomized controlled trial; ROPI=ropivacaine; RSS=Ramsey
sedation scale; TEC=thoracic epidural catheter; TRT=treatment;
VAS=visual analogue scale; VRS=verbal rating score</p></fn></table-wrap-foot></table-wrap><sec><title>Outcomes Among the Trials</title><p>The reviewed trials reported several outcomes. Only the outcomes pertinent to
our review were described. The primary or secondary outcomes of included
studies were sufentanil (SUF) consumption<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r19" ref-type="bibr">19</xref>]</sup>, the mean of pain
intensity<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r17" ref-type="bibr">17</xref>-<xref rid="r20" ref-type="bibr">20</xref>,<xref rid="r22" ref-type="bibr">22</xref>,<xref rid="r23" ref-type="bibr">23</xref>]</sup>, the median of
POP<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>, the number of patient controlled intravenous
analgesia (PCIA) self-administer<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>, the number of opioid
injection<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r20" ref-type="bibr">20</xref>]</sup>,
morphine consumption<sup>[<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r21" ref-type="bibr">21</xref>,<xref rid="r23" ref-type="bibr">23</xref>,<xref rid="r25" ref-type="bibr">25</xref>]</sup>, the number of intraoperative anesthetic
drug requirements<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>, fentanyl consumption<sup>[<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r24" ref-type="bibr">24</xref>]</sup>, postoperative analgesic
requirements<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>, need for additional epidural
bupivacaine<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>, and the incidence of POP<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>. The pain was
evaluated from one to 72 hours after the operation. <xref rid="t3" ref-type="table">Table 3</xref> depicts the additional details for
characteristics of included trials.</p><p>
<xref rid="t4" ref-type="table">Table 4</xref> briefly shows a list of the
preliminary findings of this review.</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>The most relevant preliminary findings of our review.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="100%" span="1"/></colgroup><tbody><tr><td align="left" rowspan="1" colspan="1">&#x02022; DEX is associated with lower
postoperative pain scores or incidence after cardiothoracic
surgeries in comparison with placebo (normal saline)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; DEX is probability able to reduce the
analgesia requirement during and after cardiothoracic
surgeries</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; DEX is unable to reduce the
postoperative pain score or incidence after 36 hours from
the start of surgery</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; DEX is probability able to improve the
postoperative pain control in comparison with morphine</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; DEX has noticeable morphine-sparing
effects</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; DEX could decrease intravenous
morphine consumption during ICU stay</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; DEX could improve the analgesic effect
of sufentanil and decrease the total dosage of sufentanil
during the first 24 hours after surgery</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; The addition of DEX to epidural
bupivacaine could decrease the anesthetic requirements and
improve postoperative analgesia</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; DEX could decrease the total
consumption of narcotics</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; DEX could decrease the extubation
time</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; The most reported complications of DEX
were bradycardia, hypotension, and over sedation</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; DEX administration is associated with
lower risk of respiratory depression</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; DEX demonstrated hemodynamic
predictability.</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>Note: Due to the limited number of available trials regarding the
effectiveness of DEX, these findings are preliminary; hence,
confirmation or rejection of any of these findings warrants
further research.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>The DEX Administration Protocol</title><p>
<xref rid="t5" ref-type="table">Table 5</xref> summarized the protocol of
DEX administration among trials. Five studies<sup>[<xref rid="r15" ref-type="bibr">15</xref>-<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r21" ref-type="bibr">21</xref>,<xref rid="r22" ref-type="bibr">22</xref>]</sup> used DEX in the
intraoperative period while seven studies<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r18" ref-type="bibr">18</xref>-<xref rid="r20" ref-type="bibr">20</xref>,<xref rid="r23" ref-type="bibr">23</xref>-<xref rid="r25" ref-type="bibr">25</xref>]</sup>
used DEX in the postoperative period. Dosage for the intravenous infusion
ranged from 0.02 to 0.7 mcg/kg/h and for the epidural catheter was 1.0
mcg/kg<sup>[<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r22" ref-type="bibr">22</xref>]</sup>. Two studies added
the DEX to the patient-controlled intravenous analgesia (PCIA) pump (dosage
ranged from 0.2 to 4 mcg/kg)<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r23" ref-type="bibr">23</xref>]</sup>.
The duration of DEX administration among the trials was varied and ranged
from one to 72 hours.</p><table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Protocol for DEX administration in the DEX group.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="30%" span="1"/><col width="30%" span="1"/><col width="40%" span="1"/></colgroup><thead><tr><th align="left" scope="col" rowspan="1" colspan="1">Study, year</th><th align="left" scope="col" rowspan="1" colspan="1">Time and route of injection</th><th align="left" scope="col" rowspan="1" colspan="1">Protocol for DEX injection in DEX
group</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Dong et al.<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>, 2017</td><td align="left" rowspan="1" colspan="1">Start: Postoperatively, after transfer to the
general ward End: after 48h; Route: IV using PCIA</td><td align="left" rowspan="1" colspan="1">A PCIA protocol consists of sufentanil 3 mcg/kg
and 8 mg ondansetron was started for all patients. The PCIA
was programmed to deliver a 2ml bolus with a lockout
interval of 10 min, and a background infusion rate of 4
ml/h.<break/>DEX 4 mcg/kg was added to the PCIA for DEX
group.</td></tr><tr><td align="left" rowspan="1" colspan="1">Dutta et al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>, 2017</td><td align="left" rowspan="1" colspan="1">Start: Intraoperatively, before induction of
anesthesia<break/>End: after 72h post-operative
period;<break/>Route: epidural catheter</td><td align="left" rowspan="1" colspan="1">All patients received the study medications
through paravertebral (multipored epidural) catheter.
Patients in the DEX group received 15 mL of 0.75%
ropivacaine plus DEX, 1 mg/kg bolus over 3-to-5 minutes
followed by an infusion of 0.2% ropivacaine plus 0.2 mg/kg/h
of dexmedetomidine at 0.1 mL/kg/h.<break/>Paravertebral
infusion was stopped and the catheter was removed 72h after
surgery.</td></tr><tr><td align="left" rowspan="1" colspan="1">Jabbary Moghaddam et al.<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>,
2016</td><td align="left" rowspan="1" colspan="1">Start: Intraoperatively, after
induction;<break/>End: ?h after extubation in
ICU;<break/>Route: IV infusion</td><td align="left" rowspan="1" colspan="1">0.5 mcg/kg/h of DEX was infused from the
initiation of anesthesia until extubation in the ICU.</td></tr><tr><td align="left" rowspan="1" colspan="1">Cai et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>, 2016</td><td align="left" rowspan="1" colspan="1">Start: Intraoperatively, before the start of
anesthesia End: 30min before the end of surgery; Route: IV
infusion</td><td align="left" rowspan="1" colspan="1">Before anesthesia, patients were administered a
loading dose of 1 mg/kg DEX for 10min, followed by
continuous infusion at 0.5 mg/kg/h until 30min before the
end of surgery.</td></tr><tr><td align="left" rowspan="1" colspan="1">Priye et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>, 2015</td><td align="left" rowspan="1" colspan="1">Start: Post-operative, after transfer to ICU;
End: after 12h; Route: IV infusion</td><td align="left" rowspan="1" colspan="1">After surgery, patients were transferred
intubated and ventilated to the ICU to receive 12h infusion
of DEX 0.4 mcg/kg/h without a loading dose.</td></tr><tr><td align="left" rowspan="1" colspan="1">Ren et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>, 2015</td><td align="left" rowspan="1" colspan="1">Start: Postoperatively, after patients were
transferred to PACU; End: after 72h; Route: IV using
PCIA</td><td align="left" rowspan="1" colspan="1">All patient received DEX
intraoperatively.<break/>After surgery, 2 doses of DEX in
addition of sufentanil were compared with sufentanil using
same PCIA protocol. PCIA was programmed to deliver a bolus
dose of 2 mL, with background infusion of 2 mL/h and a
lockout of 5min, 4h limit of 40 mL.</td></tr><tr><td align="left" rowspan="1" colspan="1">Ramsay et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>, 2014</td><td align="left" rowspan="1" colspan="1">Start: Postoperatively, 18 to 24h after surgery
when patients were admitted to the telemetry unit; End:
After 24h;<break/>Route: IV infusion</td><td align="left" rowspan="1" colspan="1">An intraoperative infusion of DEX at 0.2 to 0.5
mcg/kg/h was started for all patients that continued during
their ICU or PACU.<break/>0.1-0.5 mcg/kg/h DEX was started
about 18 to 24h after surgery when patients were admitted to
the telemetry unit for up to 24h.</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdel-Meguid<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>, 2013</td><td align="left" rowspan="1" colspan="1">Start: Intraoperatively, after
induction;<break/>End: 12h after extubation;<break/>Route:
IV infusion</td><td align="left" rowspan="1" colspan="1">DEX started by continuous infusion at 0.5
mcg/kg/h after induction of anesthesia; this was reduced to
0.3 mcg/kg/h on admission to the ICU and continued for 12h
post extubation.</td></tr><tr><td align="left" rowspan="1" colspan="1">Elhakim et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>,
2010</td><td align="left" rowspan="1" colspan="1">Start: Intraoperatively, after induction of
general anesthesia;<break/>End: after 24h; Route: epidural
catheter</td><td align="left" rowspan="1" colspan="1">The DEX group received DEX 1 mcg/kg in
combination with bupivacaine 0.5% 30-40 mg via the thoracic
epidural catheter, which was inserted at the T6-7
interspace.</td></tr><tr><td align="left" rowspan="1" colspan="1">Ghandi et al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>, 2005</td><td align="left" rowspan="1" colspan="1">Start: Postoperatively, after transfer to ICU;
End: after 24h; Route: IV using PCIA</td><td align="left" rowspan="1" colspan="1">After transfer of patients to ICU, they
received infusion of DEX 0.2 mcg via a PCIA pump in the
first 24 hours after surgery.</td></tr><tr><td align="left" rowspan="1" colspan="1">Wahlander et al.<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>,
2005</td><td align="left" rowspan="1" colspan="1">Start: Postoperatively, on ICU
arrival;<break/>End: after 24h; Route: IV infusion</td><td align="left" rowspan="1" colspan="1">The DEX group received an IV loading dose of
DEX of 0.5 mcg/kg over 20min, followed by continuous IV
infusion at 0.4 mcg/kg/h.</td></tr><tr><td align="left" rowspan="1" colspan="1">Venn et al.<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>, 1999</td><td align="left" rowspan="1" colspan="1">Start: Postoperatively, after transfer to ICU;
End: 6h-24h after extubation;<break/>Route: IV infusion</td><td align="left" rowspan="1" colspan="1">DEX started within 1h of arrival on the ICU
with a loading dose of 1 mcg/kg over 10min followed by a
maintenance infusion rate of 0.2-0.7 mcg/kg/h to total
maximum duration of infusion was 24h.</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>Note: "?h" means that the end time of medication was not reported
by Jabbary Moghaddam.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Interventions for Control Group</title><p>Different comparators with DEX were placebo (normal saline) in 9 study
arms<sup>[<xref rid="r14" ref-type="bibr">14</xref>-<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r20" ref-type="bibr">20</xref>,<xref rid="r21" ref-type="bibr">21</xref>,<xref rid="r24" ref-type="bibr">24</xref>,<xref rid="r25" ref-type="bibr">25</xref>]</sup>, different dosages of DEX with SUF 0.02
mcg/kg/h in 1 arm<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>, morphine in 1 arm<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup> and bupivacaine in
1 arm<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>.</p></sec><sec><title>DEX versus Placebo</title><p>Nine trials compared DEX with placebo. Intraoperative administration of DEX
was compared with placebo (normal saline) in four trials<sup>[<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r21" ref-type="bibr">21</xref>]</sup>, while
postoperative administration of DEX was compared with placebo (normal
saline) in five trials<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r20" ref-type="bibr">20</xref>,<xref rid="r24" ref-type="bibr">24</xref>,<xref rid="r25" ref-type="bibr">25</xref>]</sup>.
All of these nine trials showed significant lower POP scores in the DEX
group. In general, intra- and postoperative administration of DEX could
reduce the pain intensity score after surgery in comparison with
placebo.</p></sec><sec><title>DEX versus Morphine</title><p>In comparison with morphine (0.2 mg via PCIA), administration of DEX 4
mcg/kg/h via PCIA could improve the pain control during the first 12 hours
after surgery and decrease intravenous morphine consumption during ICU
stay<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>.</p></sec><sec><title>DEX Addition to Bupivacaine</title><p>One study compared the addition of DEX (1 mcg/kg) to epidural bupivacaine
0.5% with epidural bupivacaine 0.5% and found that epidural use of DEX could
decrease the anesthetic requirements and improve postoperative
analgesia<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>.</p></sec></sec><sec><title>Main Outcomes</title><sec><title>Post-Operative Pain Intensity or Incidence</title><p>Nine trials reported the POP scores at different time
points<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r17" ref-type="bibr">17</xref>-<xref rid="r23" ref-type="bibr">23</xref>]</sup>.
<xref rid="t6" ref-type="table">Table 6</xref> shows the POP scores at
different time points, which were significantly lower in the DEX group. Only
one trial<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup> showed a significant lower pain intensity 36
hours after surgery in the DEX group. The incidence of POP in the DEX group
was significantly lower in the DEX group when DEX was administered
intraoperatively via IV route<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>. The median of POP was significantly lower
at all time points up to 24 hours in DEX group when DEX was administered
intraoperatively via IV route<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>. The POP scores and morphine consumption
were significantly lower in the DEX group when DEX was used intraoperatively
via epidural catheter<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. In all of the trials, no significant
difference was found between groups 48 and 72 hours after surgery in terms
of POP scores. In general, DEX probably is able to reduce the pain intensity
score after CTS up to 24 hours.</p><table-wrap id="t6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Significant lower pain score at different time points after
surgery.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="35%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Study, year</th><th align="center" colspan="13" rowspan="1">Time points in hour after
surgery</th></tr><tr><th align="center" rowspan="1" colspan="1">1</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">2</th><th align="center" rowspan="1" colspan="1">4</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">6</th><th align="center" rowspan="1" colspan="1">8</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">10</th><th align="center" rowspan="1" colspan="1">12</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">16</th><th align="center" rowspan="1" colspan="1">18</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">24</th><th align="center" rowspan="1" colspan="1">36</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">48</th><th align="center" rowspan="1" colspan="1">72</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Dong et al.<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>, 2017</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Dutta et al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>, 2017</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Jabbary Moghaddam et al.<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>,
2016</td><td align="center" colspan="13" rowspan="1">The incidence of postoperative
pain was reported</td></tr><tr><td align="left" rowspan="1" colspan="1">Cai et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>, 2016</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Priye et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>, 2015</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Ren et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>, 2015</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Ramsay et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>, 2014</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdel-Meguid<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>, 2013</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Elhakim et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>,
2010</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Ghandi et al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>, 2005</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Wahlander et al.<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>,
2005</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">*</xref></td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Venn et al.<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>, 1999</td><td align="center" colspan="13" rowspan="1">Pain was not reported</td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><p>Note for interpretation:</p></fn><fn id="TFN6"><label>*</label><p>Pain score was significantly lower in the DEX group at (the
desired hour) after surgery in comparison with the control
group.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>The Post-Operative Narcotics and/or Analgesic Requirements</title><p>Ten studies<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r19" ref-type="bibr">19</xref>-<xref rid="r25" ref-type="bibr">25</xref>]</sup> found that the
total consumption of narcotics was significantly lower in the DEX group. The
requirement for postoperative rescue sedation and analgesia in DEX group was
significantly lower when DEX was administered postoperatively via
intravenous route<sup>[<xref rid="r24" ref-type="bibr">24</xref>,<xref rid="r25" ref-type="bibr">25</xref>]</sup>.
One study compared the addition of different dosage of DEX (0.02 and 0.04
mcg/kg/h) to SUF with SUF 0.02 mcg/kg/h. The addition of DEX 0.04 mcg/kg/h
to SUF could improve the analgesic effect of SUF and decrease the total
dosage of SUF during the first 72 hours after surgery<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>. In general, DEX
administration probably is able to reduce the requirements for supplemental
narcotic, rescue sedation and analgesia in the postoperative period for up
to 24 hours.</p></sec><sec><title>DEX Adverse Events</title><p>Only six trials (n=206) have reported the adverse events of DEX
administration. In all of those trials, DEX was administered postoperatively
through intravenous injection or using PCIA. As depicted in <xref rid="t7" ref-type="table">Table 7</xref>, the differences between two
groups regarding the adverse events were not statistically significant,
except for the occurrence of atelectasis, which was significantly higher in
the control group (OR 0.400, CI 95%: 0.177-0.904). Because of incomplete
report of some trials, the adverse events rate was not comparable among
patients who received DEX intraoperatively and postoperatively. Therefore,
the duration and timing of DEX administration (short <italic>vs</italic>.
prolonged) on the incident of adverse events was not evaluated.</p><table-wrap id="t7" orientation="portrait" position="float"><label>Table 7</label><caption><p>The comparison of adverse events between DEX and Control groups.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Adverse Events</th><th align="center" rowspan="1" colspan="1">In DEX (n)</th><th align="center" rowspan="1" colspan="1">In Control (n)</th><th align="center" rowspan="1" colspan="1">Odds ratio (CI 95%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation</td><td align="center" rowspan="1" colspan="1">10 (53)</td><td align="center" rowspan="1" colspan="1">6 (56)</td><td align="center" rowspan="1" colspan="1">1.998 (0.272-14.660)</td></tr><tr><td align="left" rowspan="1" colspan="1">Bradycardia</td><td align="center" rowspan="1" colspan="1">7 (62)</td><td align="center" rowspan="1" colspan="1">4 (62)</td><td align="center" rowspan="1" colspan="1">1.448 (0.158-13.247)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypotension</td><td align="center" rowspan="1" colspan="1">16 (115)</td><td align="center" rowspan="1" colspan="1">6 (118)</td><td align="center" rowspan="1" colspan="1">3.453 (0.714-16.698)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea/Vomiting</td><td align="center" rowspan="1" colspan="1">59 (208)</td><td align="center" rowspan="1" colspan="1">80 (213)</td><td align="center" rowspan="1" colspan="1">0.641 (0.209-1.962)</td></tr><tr><td align="left" rowspan="1" colspan="1">Pruritus</td><td align="center" rowspan="1" colspan="1">18 (153)</td><td align="center" rowspan="1" colspan="1">45 (153)</td><td align="center" rowspan="1" colspan="1">0.260 (0.068-1.000)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">4 (30)</td><td align="center" rowspan="1" colspan="1">7 (30)</td><td align="center" rowspan="1" colspan="1">0.505 (0.131-1.951)</td></tr><tr><td align="left" rowspan="1" colspan="1">Respiratory depression</td><td align="center" rowspan="1" colspan="1">4 (30)</td><td align="center" rowspan="1" colspan="1">9 (30)</td><td align="center" rowspan="1" colspan="1">0.359 (0.096-1.331)</td></tr><tr><td align="left" rowspan="1" colspan="1">Atelectasis</td><td align="center" rowspan="1" colspan="1">23 (50)</td><td align="center" rowspan="1" colspan="1">34 (50)</td><td align="center" rowspan="1" colspan="1">0.400 (0.177-0.904)</td></tr><tr><td align="left" rowspan="1" colspan="1">Delirium</td><td align="center" rowspan="1" colspan="1">8 (41)</td><td align="center" rowspan="1" colspan="1">12 (41)</td><td align="center" rowspan="1" colspan="1">0.585 (0.210-1.631)</td></tr></tbody></table></table-wrap><p>The most reported complications of DEX were nausea/vomiting<sup>[<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r19" ref-type="bibr">19</xref>,<xref rid="r20" ref-type="bibr">20</xref>,<xref rid="r23" ref-type="bibr">23</xref>,<xref rid="r25" ref-type="bibr">25</xref>]</sup>, bradycardia<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r25" ref-type="bibr">25</xref>]</sup> and
hypotension<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r20" ref-type="bibr">20</xref>,<xref rid="r24" ref-type="bibr">24</xref>,<xref rid="r25" ref-type="bibr">25</xref>]</sup>.
Two studies did not report DEX complications<sup>[<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r21" ref-type="bibr">21</xref>]</sup> and four studies reported no statistically
significant complications between groups<sup>[<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r19" ref-type="bibr">19</xref>,<xref rid="r22" ref-type="bibr">22</xref>,<xref rid="r23" ref-type="bibr">23</xref>]</sup>. One of the included trials reported four
events of respiratory depression in the DEX group<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>.</p></sec></sec><sec><title>Other Outcomes</title><p>The clinical efficacy of DEX on the ICU length of stay was only reported by one
study, which showed that ICU stay was significantly shorter in the DEX group
than in the control group (2 and 3 days, respectively)<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>. DEX efficacy on the
time spent on the ventilator was not reported by any of the included trials. In
addition, the information regarding the number of patients who admitted to the
ICU after surgery and the duration of ICU stay were not clearly reported across
the reviewed trials.</p></sec><sec><title>Dealing with Missing Data</title><p>In four cases, we contacted the corresponding author to request further
information regarding random sequence generation, allocation concealment,
additional blinding details, and type of surgery without success and in one case
the contact address was not retrievable.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Pain management after CTS is an important issue for clinicians because POP can
significantly impair the cardiovascular and respiratory function. The present study,
including 12 RCTs, reviewed the effectiveness of DEX in reducing POP. Regardless of
the methodological quality of included studies, the overall results are relatively
consistent among studies. Approximately all included studies were methodologically
homogenous; however, they were different in the sample size, use of analgesic and
anesthetic agent, number of measured outcomes, study population, route and timing of
DEX administration and type of surgery.</p><p>Findings from our review suggest that, compared with normal saline as a placebo, DEX
probably is able to reduce the pain intensity score, the number of narcotic
consumption and analgesic requirements up to 24 hours. However, due to the low to
medium quality of reviewed trials, further studies are warranted to confirm or
refute our findings.</p><p>Our finding may have noteworthy implications for pain management of adults' patients
undergoing CTS, particularly in the first 24 hours after surgery. It is necessary to
mention that the use of DEX beyond 24 hours may be associated with a dose-related
increase in adverse events and for this reason, the Food and Drug Administration
(FDA) has not recommended the use of DEX for more than 24 hours<sup>[<xref rid="r27" ref-type="bibr">27</xref>,<xref rid="r28" ref-type="bibr">28</xref>]</sup>. However, the safe use of this drug has been
reported from 24 hours to more than a week<sup>[<xref rid="r28" ref-type="bibr">28</xref>,<xref rid="r29" ref-type="bibr">29</xref>]</sup>.</p><p>In the present review, the detailed comparison of the results of the included trials
was not possible due to differences in intervention protocol and outcomes
measurement. Additionally, five of 12 trials<sup>[<xref rid="r20" ref-type="bibr">20</xref>-<xref rid="r23" ref-type="bibr">23</xref>,<xref rid="r25" ref-type="bibr">25</xref>]</sup> were likely underpowered
for the outcomes, since they did not power the sample size. Therefore, the optimal
dosage, timing, and route of DEX administration remain to be elucidated in future
studies.</p><p>Previous studies have revealed that the most effective dosage of DEX for maximum POP
reduction is a loading dose of 1 mcg/kg, which is followed by a continuous infusion
of 0.5-1 mcg/kg/h<sup>[<xref rid="r30" ref-type="bibr">30</xref>]</sup>. In our review, the dosage for the intravenous infusion
were ranged from 0.02 to 0.7 mcg/kg/h and only two studies<sup>[<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r25" ref-type="bibr">25</xref>]</sup> infused DEX at maximum POP reduction dose. We also
found that a limited number of studies suggested a scientific justification of the
rationale for choosing a dose.</p><p>The common adverse events of DEX are hypotension at low blood concentrations,
hypertension at high blood concentrations, bradycardia and nausea<sup>[<xref rid="r29" ref-type="bibr">29</xref>]</sup>. Most of these side
effects occur at infusion of 0.2-0.7 mcg/kg/h without a bolus dose<sup>[<xref rid="r28" ref-type="bibr">28</xref>,<xref rid="r31" ref-type="bibr">31</xref>]</sup>. In our review, the occurrence of respiratory
depression was low and reported only in one trials<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>, which is consistent with previous
studies<sup>[<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r28" ref-type="bibr">28</xref>,<xref rid="r31" ref-type="bibr">31</xref>]</sup>. Previous study showed that respiratory suppression
does not even occur at DEX plasma levels up to 8.0 ng/mL and only there is a risk of
over-sedation<sup>[<xref rid="r32" ref-type="bibr">32</xref>]</sup>.</p><p>DEX possesses analgesic and opioid-sparing effects in the ICU
patients<sup>[<xref rid="r33" ref-type="bibr">33</xref>]</sup>. DEX, a shorter-acting and highly selective presynaptic
alpha-2-receptor agonist, also possesses pharmacologic sedative, hypnotic,
anti-anxious, sympatholytic and analgesic properties<sup>[<xref rid="r28" ref-type="bibr">28</xref>]</sup>. Its analgesic and
opioid-sparing effects are dose-dependent and trigger at spinal cord sites as well
as through non-spinal mechanisms<sup>[<xref rid="r29" ref-type="bibr">29</xref>]</sup>. It has been suggested that alpha-2A receptors
activation, inhibition of the C and A delta fibers signals conduction, and the local
release of encephalin are the underlying non-spinal mechanisms of DEX to provide
anti-nociception effects<sup>[<xref rid="r34" ref-type="bibr">34</xref>]</sup>. In terms of pharmacokinetics, its action starts about
15 minutes after intravenous injection and its peak concentration is achieved within
an hour of continuous intravenous infusion. Appropriate pharmacodynamic effects of
DEX are revealed between the plasma concentration of 0.5 and 1.2 ng/ml.</p><p>Several strategies have been introduced for POP management<sup>[<xref rid="r35" ref-type="bibr">35</xref>]</sup>. It is believed that
multimodal analgesic approaches combining different analgesic agents with different
mechanisms of action can maximize pain relief while minimize the opioid consumption
and thus can limit the opioid-induced side effects<sup>[<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r36" ref-type="bibr">36</xref>]</sup>.
As a method of limiting opioid-induced adverse events, therefore, multimodal POP
management has the potential to decrease morbidity and mortality after
surgery<sup>[<xref rid="r35" ref-type="bibr">35</xref>]</sup>.
Consequently, it is expected that the sedative, anesthetic, analgesic, and
cardiorespiratory effects of DEX may enhance with concomitant administration with
other anesthetic, sedative and analgesic medications<sup>[<xref rid="r28" ref-type="bibr">28</xref>]</sup>. In our review, regardless
of the route of administration, three studies used the multimodal approaches and
found a reduction in the narcotic consumption and supplemental analgesics
requirements<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r19" ref-type="bibr">19</xref>]</sup>. In addition, two studies found that the addition
of DEX to morphine can reduce the opioid consumption<sup>[<xref rid="r20" ref-type="bibr">20</xref>,<xref rid="r21" ref-type="bibr">21</xref>]</sup>, the risk of respiratory
depression<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup> and the time of extubation<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>. One study found that
epidural use of DEX plus bupivacaine 0.5% plus fentanyl can decrease the anesthetic
requirements and provides effective post-operative analgesia<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>. It should be noted that
the peridural (epidural) form of DEX has not been officially approved by any drug
administrations around the world. However, in many clinical practices, the off-label
form of DEX has been used in various scenarios in the operating room including
thoracic epidural anesthesia, regional anesthesia block, intubation, monitored
anesthesia care sedation, cardiothoracic surgery, and neurosurgery. The United
States FDA has only approved the form of intravenous injection of
DEX<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup>.</p><p>As the findings of our review suggest, several advantages may encourage clinicians to
use DEX over other agents for POP reduction. First, DEX does not interfere with
respiratory function and has predictable and stable hemodynamic responses. Second,
because of its synergistic effects with narcotics and sedatives, DEX can be used to
reduce the total dosage of those drugs. Third, DEX has anxiolytic and sedative
properties that may improve POP control. Forth, DEX can be used as an adjuvant to
local anesthesia; hence, it can improve postoperative analgesia, and reduce the
opioid requirement. Fifth, technically, the use of intravenous DEX is easier that
paravertebral or peridural route in terms of equipment, skill, and side effects.</p><p>These advantages are consistent with the finding of several reviews that have
emphasized the analgesic effects of DEX on POP in different sample of patients and
surgeries. Schnabel et al.<sup>[<xref rid="r30" ref-type="bibr">30</xref>]</sup> found that the IV administration of DEX compared with
placebo or opioids reduces acute POP and opioid consumption, as well as declines the
risk of opioid-related adverse events in patients undergoing non-thoracotomy
surgeries. Peng et al.<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup> found that postoperative PCIA protocols containing
opioid-DEX combination have beneficial effects for reducing the POP intensity,
postoperative morphine-equivalent consumption and the adverse events. Liu et
al.<sup>[<xref rid="r37" ref-type="bibr">37</xref>]</sup>
reviewed the efficacy of DEX on perioperative opioid consumption and POP intensity
of patients undergoing neurosurgery and found that DEX could reduce opioid
consumption and POP intensity. Bellon et al.<sup>[<xref rid="r38" ref-type="bibr">38</xref>]</sup> found that the intraoperative
administration of DEX could reduce postoperative opioids consumption and POP
intensity in children undergoing surgery.</p><p>There are also some studies demonstrating that administration of DEX cannot reduce
POP. Jessen Lundorf et al.<sup>[<xref rid="r39" ref-type="bibr">39</xref>]</sup> concluded that perioperative administration of DEX in
comparison with placebo seems to have some opioid-sparing effect with no important
differences in POP in adult patients undergoing abdominal surgery. Tan and
Ho<sup>[<xref rid="r40" ref-type="bibr">40</xref>]</sup>
showed that DEX might reduce the length of ICU stay and duration of mechanical
ventilation, but increases the risk of bradycardia and hypotension in critically ill
adult patients.</p><sec><title>Limitations</title><p>This systematic review has some limitations. First, we did not judge regarding
the quality of each trials and risk of bias due to the limit number of retrieved
trials; however, we used the Cochrane risk assessment tool to demonstrate any
risk of bias at each domain. Second, due to the considerable heterogeneity
between studies, we could not perform meta-analysis to evaluate statistically
the efficacy of DEX over the other analgesic agents. Third, due to the lack of
reported data in some of the trials, difference in DEX doses, and different
times of administration, we could not synthesis the results based on the
subgroups. Forth, the outcome of pain was incompletely measured and reported in
some trials; hence, we could not critically appraise the outcome of those
trials. Fifth, we cannot compare the DEX group with control group regarding the
POP scores based on the type of surgery because the number of patients in
subcategories of cardiac surgery was reported incompletely.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>In comparison with placebo or other analgesic agents, the use of DEX after CTS is
associated with a lower POP intensity, a lower number of post-operative analgesic
requirements and a lower number of adverse events, particularly respiratory
depression. Thus, DEX can be used as a safe and efficient analgesic agent for
reducing the POP up to 24 hours. Overall, data published to date regarding the use
of DEX after CTS suggest a marginal clinical benefit. Further well-designed studies
with powered sample size are needed to find the optimal dosage, route, time, and
duration of administration as well as the best choice of adjuvant analgesia to DEX
for reducing POP.</p><table-wrap id="t9" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">VH</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FHK</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HS</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Mazandaran University of Medical Sciences, Sari,
Iran.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><app-group><app id="app1"><label>APPENDIX A</label><p>Keywords for PubMed</p><p>("adrenergic alpha-2 receptor agonists"[MeSH Terms] OR
dexmedetomidine[Title/Abstract]) AND ("pain"[MeSH
Terms] OR pain[Title/Abstract] OR
analgesia[Title/Abstract] OR
analgesic[Title/Abstract]) AND (Clinical Trial[ptyp]
AND "humans"[MeSH Terms] AND English[lang]) AND
(Clinical Trial[ptyp] AND "humans"[MeSH Terms] AND
English[lang]) =294</p><p>SCOPUS (2017-June-15)</p><p>TITLE-ABS-KEY ( dexmedetomidine ) OR TITLE-ABS-KEY ( "adrenergic alpha 2 receptor
agonist" ) AND TITLE-ABS-KEY ( pain ) AND ( LIMIT-TO ( DOCTYPE , "ar" ) OR
LIMIT-TO ( DOCTYPE , "ip" ) ) AND ( LIMIT-TO ( EXACTKEYWORD , "Human" ) OR
LIMIT-TO ( EXACTKEYWORD , "Humans" ) ) AND ( LIMIT-TO ( LANGUAGE , "English" ) )
AND ( LIMIT-TO ( SRCTYPE , "j" ) )=701</p><p>ISI (2017-June-15)</p><p>(TS=(dexmedetomidine AND pain)) AND LANGUAGE: (English) AND DOCUMENT TYPES:
(Article)=617</p><p>Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</p><p>Cochrane (2017-June-17)</p><p>#1 MeSH descriptor: [Pain] explode all trees</p><p>#2 MeSH descriptor: [Adrenergic alpha-2 Receptor Agonists] explode
all trees</p><p>#3 MeSH descriptor: [Dexmedetomidine] explode all trees</p><p>#4 (#1 and #2) or (#1 and #4) in Trials= 165</p></app></app-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attri</surname><given-names>JP</given-names></name><name><surname>Kaur</surname><given-names>R</given-names></name><name><surname>Kaur</surname><given-names>H</given-names></name><name><surname>Makhni</surname><given-names>R</given-names></name></person-group><article-title>Post thoracotomy pain management: a review of current available
modalities</article-title><source>Northern J ISA</source><year>2016</year><volume>1</volume><issue>1</issue><fpage>7</fpage><lpage>10</lpage></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Aldrete</surname><given-names>D</given-names></name><name><surname>Candiotti</surname><given-names>KA</given-names></name><name><surname>Janakiraman</surname><given-names>R</given-names></name><name><surname>Rodriguez-Blanco</surname><given-names>YF</given-names></name></person-group><article-title>Trends and new evidence in the management of acute and chronic
post-thoracotomy pain: an overview of the literature from 2005 to
2015</article-title><source>J Cardiothorac Vasc Anesth</source><year>2016</year><volume>30</volume><issue>3</issue><fpage>762</fpage><lpage>772</lpage><pub-id pub-id-type="pmid">26597765</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerner</surname><given-names>P</given-names></name></person-group><article-title>Post-thoracotomy pain management problems</article-title><source>Anesthesiol Clin</source><year>2008</year><volume>26</volume><issue>2</issue><fpage>355</fpage><lpage>vii</lpage><pub-id pub-id-type="pmid">18456219</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottschalk</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>SP</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Ochroch</surname><given-names>E</given-names></name></person-group><article-title>Preventing and treating pain after thoracic
surgery</article-title><source>Anesthesiology</source><year>2006</year><volume>104</volume><issue>3</issue><fpage>594</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">16508407</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komatsu</surname><given-names>T</given-names></name><name><surname>Sowa</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Fujinaga</surname><given-names>T</given-names></name></person-group><article-title>Paravertebral block as a promising analgesic modality for
managing post-thoracotomy pain</article-title><source>Ann Thorac Cardiovasc Surg</source><year>2014</year><volume>20</volume><issue>2</issue><fpage>113</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">23445804</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maxwell</surname><given-names>C</given-names></name><name><surname>Nicoara</surname><given-names>A</given-names></name></person-group><article-title>New developments in the treatment of acute pain after thoracic
surgery</article-title><source>Curr Opin Anaesthesiol</source><year>2014</year><volume>27</volume><issue>1</issue><fpage>6</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">24296973</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heidari Gorji</surname><given-names>MA</given-names></name><name><surname>Ashrastaghi</surname><given-names>OG</given-names></name><name><surname>Habibi</surname><given-names>V</given-names></name><name><surname>Charati</surname><given-names>JY</given-names></name><name><surname>Ebrahimzadeh</surname><given-names>MA</given-names></name><name><surname>Ayasi</surname><given-names>M</given-names></name></person-group><article-title>The effectiveness of lavender essence on strernotomy related pain
intensity after coronary artery bypass grafting</article-title><source>Adv Biomed Res</source><year>2015</year><volume>4</volume><fpage>127</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">26261829</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rice</surname><given-names>DC</given-names></name><name><surname>Cata</surname><given-names>JP</given-names></name><name><surname>Mena</surname><given-names>GE</given-names></name><name><surname>Rodriguez-Restrepo</surname><given-names>A</given-names></name><name><surname>Correa</surname><given-names>AM</given-names></name><name><surname>Mehran</surname><given-names>RJ</given-names></name></person-group><article-title>Posterior intercostal nerve block with liposomal bupivacaine: an
alternative to thoracic epidural analgesia</article-title><source>Ann Thorac Surg</source><year>2015</year><volume>99</volume><issue>6</issue><fpage>1953</fpage><lpage>1960</lpage><pub-id pub-id-type="pmid">25912739</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>HY</given-names></name><name><surname>Wu</surname><given-names>SR</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name><name><surname>Ji</surname><given-names>FH</given-names></name></person-group><article-title>Effects of combining dexmedetomidine and opioids for
postoperative intravenous patient-controlled analgesia: a systematic review
and meta-analysis</article-title><source>Clin J Pain</source><year>2015</year><volume>31</volume><issue>12</issue><fpage>1097</fpage><lpage>1104</lpage><pub-id pub-id-type="pmid">25654534</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Comparison of the pro-postoperative analgesia of intraoperative
dexmedetomidine with and without loading dose following general anesthesia:
a prospective, randomized, controlled clinical trial</article-title><source>Medicine</source><publisher-loc>Baltimore</publisher-loc><year>2017</year><volume>96</volume><issue>7</issue><elocation-id>e6106</elocation-id><pub-id pub-id-type="pmid">28207529</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barr</surname><given-names>J</given-names></name><name><surname>Fraser</surname><given-names>GL</given-names></name><name><surname>Puntillo</surname><given-names>K</given-names></name><name><surname>Ely</surname><given-names>EW</given-names></name><name><surname>G&#x000e9;linas</surname><given-names>C</given-names></name><name><surname>Dasta</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Clinical practice guidelines for the management of pain,
agitation, and delirium in adult patients in the intensive care
unit</article-title><source>Crit Care Med</source><year>2013</year><volume>41</volume><issue>1</issue><fpage>263</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">23269131</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>HH</given-names></name><name><surname>Wang</surname><given-names>HT</given-names></name><name><surname>Jin</surname><given-names>JJ</given-names></name><name><surname>Cui</surname><given-names>GB</given-names></name><name><surname>Zhou</surname><given-names>KC</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Does dexmedetomidine as a neuraxial adjuvant facilitate better
anesthesia and analgesia? A systematic review and
meta-analysis</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>3</issue><elocation-id>e93114</elocation-id><pub-id pub-id-type="pmid">24671181</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Liberati</surname><given-names>A</given-names></name><name><surname>Tetzlaff</surname><given-names>J</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><collab>PRISMA Group</collab></person-group><article-title>Preferred reporting items for systematic reviews and
meta-analyses: the PRISMA statement</article-title><source>Int J Surg</source><year>2010</year><volume>8</volume><issue>5</issue><fpage>336</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">20171303</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>CS</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>JM</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Effect of dexmedetomidine combined with sufentanil for
post-thoracotomy intravenous analgesia:a randomized, controlled clinical
study</article-title><source>BMC Anesthesiol</source><year>2017</year><volume>17</volume><issue>1</issue><fpage>33</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">28249614</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutta</surname><given-names>V</given-names></name><name><surname>Kumar</surname><given-names>B</given-names></name><name><surname>Jayant</surname><given-names>A</given-names></name><name><surname>Mishra</surname><given-names>AK</given-names></name></person-group><article-title>Effect of continuous paravertebral dexmedetomidine administration
on intraoperative anesthetic drug requirement and post-thoracotomy pain
syndrome after thoracotomy: a randomized controlled trial</article-title><source>J Cardiothorac Vasc Anesth</source><year>2017</year><volume>31</volume><issue>1</issue><fpage>159</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">27554227</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabbary Moghaddam</surname><given-names>M</given-names></name><name><surname>Barkhori</surname><given-names>A</given-names></name><name><surname>Mirkheshti</surname><given-names>A</given-names></name><name><surname>Hashemian</surname><given-names>M</given-names></name><name><surname>Amir Mohajerani</surname><given-names>S</given-names></name></person-group><article-title>The effect of pre-emptive dexmedetomidine on the incidence of
post-thoracotomy pain syndrome in patients undergoing coronary artery bypass
grafting</article-title><source>Anesth Pain Med</source><year>2016</year><volume>6</volume><issue>3</issue><elocation-id>e36344</elocation-id><pub-id pub-id-type="pmid">27660748</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effects of intraoperative dexmedetomidine on postoperative pain
in highly nicotine-dependent patients after thoracic surgery: a prospective,
randomized, controlled trial</article-title><source>Medicine</source><publisher-loc>Baltimore</publisher-loc><year>2016</year><volume>95</volume><issue>22</issue><elocation-id>e3814</elocation-id><pub-id pub-id-type="pmid">27258524</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priye</surname><given-names>S</given-names></name><name><surname>Jagannath</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Shivaprakash</surname><given-names>S</given-names></name><name><surname>Reddy</surname><given-names>DP</given-names></name></person-group><article-title>Dexmedetomidine as an adjunct in postoperative analgesia
following cardiac surgery: a randomized, double-blind study</article-title><source>Saudi J Anaesth</source><year>2015</year><volume>9</volume><issue>4</issue><fpage>353</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">26543448</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Qi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Effect of intraoperative and postoperative infusion of
dexmedetomidine on the quality of postoperative analgesia in highly
nicotine-dependent patients after thoracic surgery: a consort-prospective,
randomized, controlled trial</article-title><source>Medicine</source><publisher-loc>Baltimore</publisher-loc><year>2015</year><volume>94</volume><issue>32</issue><elocation-id>e1329</elocation-id><pub-id pub-id-type="pmid">26266376</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsay</surname><given-names>MA</given-names></name><name><surname>Newman</surname><given-names>KB</given-names></name><name><surname>Leeper</surname><given-names>B</given-names></name><name><surname>Hamman</surname><given-names>BL</given-names></name><name><surname>Hebeler Jr</surname><given-names>RF</given-names></name><name><surname>Henry</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Dexmedetomidine infusion for analgesia up to 48 hours after lung
surgery performed by lateral thoracotomy</article-title><source>Proc (Bayl Univ Med Cent)</source><year>2014</year><volume>27</volume><issue>1</issue><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">24381392</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdel-Meguid</surname><given-names>ME</given-names></name></person-group><article-title>Dexmedetomidine as anesthetic adjunct for fast tracking and pain
control in off-pump coronary artery bypass</article-title><source>Saudi J Anaesth</source><year>2013</year><volume>7</volume><issue>1</issue><fpage>6</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">23717223</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elhakim</surname><given-names>M</given-names></name><name><surname>Abdelhamid</surname><given-names>D</given-names></name><name><surname>Abdelfattach</surname><given-names>H</given-names></name><name><surname>Magdy</surname><given-names>H</given-names></name><name><surname>Elsayed</surname><given-names>A</given-names></name><name><surname>Elshafei</surname><given-names>M</given-names></name></person-group><article-title>Effect of epidural dexmedetomidine on intraoperative awareness
and post-operative pain after one-lung ventilation</article-title><source>Acta Anaesthesiol Scand</source><year>2010</year><volume>54</volume><issue>6</issue><fpage>703</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">20085547</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghandi</surname><given-names>I</given-names></name><name><surname>Alavi</surname><given-names>SM</given-names></name><name><surname>Babaee</surname><given-names>T</given-names></name><name><surname>Ghadrdoost</surname><given-names>B</given-names></name><name><surname>Bakhshandeh</surname><given-names>H</given-names></name><name><surname>Ziyaeifard</surname><given-names>M</given-names></name><etal/></person-group><article-title>The analgesic effect of morphine and dexmedetomidine intravenous
patient-controlled analgesia method to control pain after open cardiac
surgery: a randomized control trial</article-title><source>Arch Crit Care Med</source><year>2015</year><volume>1</volume><issue>3</issue><elocation-id>e6453</elocation-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahlander</surname><given-names>S</given-names></name><name><surname>Frumento</surname><given-names>RJ</given-names></name><name><surname>Wagener</surname><given-names>G</given-names></name><name><surname>Saldana-Ferretti</surname><given-names>B</given-names></name><name><surname>Joshi</surname><given-names>RR</given-names></name><name><surname>Playford</surname><given-names>HR</given-names></name><etal/></person-group><article-title>A prospective, double-blind, randomized, placebo-controlled study
of dexmedetomidine as an adjunct to epidural analgesia after thoracic
surgery</article-title><source>J Cardiothorac Vasc Anesth</source><year>2005</year><volume>19</volume><issue>5</issue><fpage>630</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">16202898</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venn</surname><given-names>RM</given-names></name><name><surname>Bradshaw</surname><given-names>CJ</given-names></name><name><surname>Spencer</surname><given-names>R</given-names></name><name><surname>Brealey</surname><given-names>D</given-names></name><name><surname>Caudwell</surname><given-names>E</given-names></name><name><surname>Naughton</surname><given-names>C</given-names></name><etal/></person-group><article-title>Preliminary UK experience of dexmedetomidine, a novel agent for
postoperative sedation in the intensive care unit</article-title><source>Anaesthesia</source><year>1999</year><volume>54</volume><issue>12</issue><fpage>1136</fpage><lpage>1142</lpage><pub-id pub-id-type="pmid">10594409</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>J</given-names></name><name><surname>Green</surname><given-names>S</given-names></name></person-group><source>Cochrane handbook for systematic reviews of interventions: the Cochrane
Collaboration</source><year>2011</year><comment>updated March 2011</comment><date-in-citation content-type="access-date">2017 June</date-in-citation><comment>5.1.0</comment><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://handbook.cochrane.org">http://handbook.cochrane.org</ext-link></comment></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popat</surname><given-names>K</given-names></name><name><surname>Purugganan</surname><given-names>R</given-names></name><name><surname>Malik</surname><given-names>I</given-names></name></person-group><article-title>Off-label uses of dexmedetomidine</article-title><source>Adv Anesthesia</source><year>2006</year><volume>24</volume><issue>Suppl C</issue><fpage>177</fpage><lpage>192</lpage></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keating</surname><given-names>GM</given-names></name></person-group><article-title>Dexmedetomidine: a review of its use for sedation in the
intensive care setting</article-title><source>Drugs</source><year>2015</year><volume>75</volume><issue>10</issue><fpage>1119</fpage><lpage>1130</lpage><pub-id pub-id-type="pmid">26063213</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panzer</surname><given-names>O</given-names></name><name><surname>Moitra</surname><given-names>V</given-names></name><name><surname>Sladen</surname><given-names>RN</given-names></name></person-group><article-title>Pharmacology of sedative-analgesic agents: dexmedetomidine,
remifentanil, ketamine, volatile anesthetics, and the role of peripheral mu
antagonists</article-title><source>Crit Care Clin</source><year>2009</year><volume>25</volume><issue>3</issue><fpage>451</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">19576524</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnabel</surname><given-names>A</given-names></name><name><surname>Meyer-Frie&#x000df;em</surname><given-names>CH</given-names></name><name><surname>Reichl</surname><given-names>SU</given-names></name><name><surname>Zahn</surname><given-names>PK</given-names></name><name><surname>Pogatzki-Zahn</surname><given-names>EM</given-names></name></person-group><article-title>Is intraoperative dexmedetomidine a new option for postoperative
pain treatment? A meta-analysis of randomized controlled
trials</article-title><source>Pain</source><year>2013</year><volume>154</volume><issue>7</issue><fpage>1140</fpage><lpage>1149</lpage><pub-id pub-id-type="pmid">23706726</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Constantin</surname><given-names>JM</given-names></name><name><surname>Momon</surname><given-names>A</given-names></name><name><surname>Mantz</surname><given-names>J</given-names></name><name><surname>Payen</surname><given-names>JF</given-names></name><name><surname>De Jonghe</surname><given-names>B</given-names></name><name><surname>Perbet</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy and safety of sedation with dexmedetomidine in critical
care patients: a meta-analysis of randomized controlled
trials</article-title><source>Anaesth Crit Care Pain Med</source><year>2016</year><volume>35</volume><issue>1</issue><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">26700947</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebert</surname><given-names>TJ</given-names></name><name><surname>Hall</surname><given-names>JE</given-names></name><name><surname>Barney</surname><given-names>JA</given-names></name><name><surname>Uhrich</surname><given-names>TD</given-names></name><name><surname>Colinco</surname><given-names>MD</given-names></name></person-group><article-title>The effects of increasing plasma concentrations of
dexmedetomidine in humans</article-title><source>Anesthesiology</source><year>2000</year><volume>93</volume><issue>2</issue><fpage>382</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">10910487</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>JE</given-names></name><name><surname>Uhrich</surname><given-names>TD</given-names></name><name><surname>Barney</surname><given-names>JA</given-names></name><name><surname>Arain</surname><given-names>SR</given-names></name><name><surname>Ebert</surname><given-names>TJ</given-names></name></person-group><article-title>Sedative, amnestic, and analgesic properties of small-dose
dexmedetomidine infusions</article-title><source>Anesth Analg</source><year>2000</year><volume>90</volume><issue>3</issue><fpage>699</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">10702460</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshitomi</surname><given-names>T</given-names></name><name><surname>Kohjitani</surname><given-names>A</given-names></name><name><surname>Maeda</surname><given-names>S</given-names></name><name><surname>Higuchi</surname><given-names>H</given-names></name><name><surname>Shimada</surname><given-names>M</given-names></name><name><surname>Miyawaki</surname><given-names>T</given-names></name></person-group><article-title>Dexmedetomidine enhances the local anesthetic action of lidocaine
via an alpha-2A adrenoceptor</article-title><source>Anesth Analg</source><year>2008</year><volume>107</volume><issue>1</issue><fpage>96</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">18635472</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bottiger</surname><given-names>BA</given-names></name><name><surname>Esper</surname><given-names>SA</given-names></name><name><surname>Stafford-Smith</surname><given-names>M</given-names></name></person-group><article-title>Pain management strategies for thoracotomy and thoracic pain
syndromes</article-title><source>Semin Cardiothorac Vasc Anesth</source><year>2014</year><volume>18</volume><issue>1</issue><fpage>45</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">24336691</pub-id></element-citation></ref><ref id="r36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devin</surname><given-names>CJ</given-names></name><name><surname>McGirt</surname><given-names>MJ</given-names></name></person-group><article-title>Best evidence in multimodal pain management in spine surgery and
means of assessing postoperative pain and functional
outcomes</article-title><source>J Clin Neurosci</source><year>2015</year><volume>22</volume><issue>6</issue><fpage>930</fpage><lpage>938</lpage><pub-id pub-id-type="pmid">25766366</pub-id></element-citation></ref><ref id="r37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Shao</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>N</given-names></name><name><surname>Gan</surname><given-names>X</given-names></name></person-group><article-title>Dexmedetomidine reduces perioperative opioid consumption and
postoperative pain intensity in neurosurgery: a
meta-analysis</article-title><source>J Neurosurg Anesthesiol</source><year>2018</year><volume>30</volume><issue>2</issue><fpage>146</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">28079737</pub-id></element-citation></ref><ref id="r38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellon</surname><given-names>M</given-names></name><name><surname>Le Bot</surname><given-names>A</given-names></name><name><surname>Michelet</surname><given-names>D</given-names></name><name><surname>Hilly</surname><given-names>J</given-names></name><name><surname>Maesani</surname><given-names>M</given-names></name><name><surname>Brasher</surname><given-names>C</given-names></name><etal/></person-group><article-title>Efficacy of intraoperative dexmedetomidine compared with placebo
for postoperative pain management: a meta-analysis of published
studies</article-title><source>Pain Ther</source><year>2016</year><volume>5</volume><issue>1</issue><fpage>63</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">26861737</pub-id></element-citation></ref><ref id="r39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jessen Lundorf</surname><given-names>L</given-names></name><name><surname>Korvenius Nedergaard</surname><given-names>H</given-names></name><name><surname>Moller</surname><given-names>AM</given-names></name></person-group><article-title>Perioperative dexmedetomidine for acute pain after abdominal
surgery in adults</article-title><source>Cochrane Database Syst Rev</source><year>2016</year><volume>2</volume><elocation-id>CD010358</elocation-id><pub-id pub-id-type="pmid">26889627</pub-id></element-citation></ref><ref id="r40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>JA</given-names></name><name><surname>Ho</surname><given-names>KM</given-names></name></person-group><article-title>Use of dexmedetomidine as a sedative and analgesic agent in
critically ill adult patients: a meta-analysis</article-title><source>Intensive Care Med</source><year>2010</year><volume>36</volume><issue>6</issue><fpage>926</fpage><lpage>939</lpage><pub-id pub-id-type="pmid">20376429</pub-id></element-citation></ref></ref-list></back></article>